These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29783018)

  • 21. Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice.
    Mengs U; Schwarz T; Bulitta M; Weber K
    Anticancer Res; 2000; 20(5B):3565-8. PubMed ID: 11131663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
    Chen F; Zhang G; Cao Y; Hessner MJ; See WA
    J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
    Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
    J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer.
    Lodillinsky C; Rodriguez V; Vauthay L; Sandes E; Casabé A; Eiján AM
    J Urol; 2009 Aug; 182(2):749-55. PubMed ID: 19539312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intravesical anchoring of streptavidin-tagged interleukin-4 fusion protein for immunotherapy of mouse superficial bladder cancer].
    Zhang Z; Xu XL; Ma L; Li JL; Hu ZM; Gao JM
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):331-5. PubMed ID: 22883451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer.
    Smith SG; Koppolu BP; Ravindranathan S; Kurtz SL; Yang L; Katz MD; Zaharoff DA
    Cancer Immunol Immunother; 2015 Jun; 64(6):689-96. PubMed ID: 25754122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model.
    Luo Y; Chen X; O'donnell MA
    J Urol; 2004 Dec; 172(6 Pt 1):2414-20. PubMed ID: 15538283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guizhi Fuling Wan as a Novel Agent for Intravesical Treatment for Bladder Cancer in a Mouse Model.
    Lu CC; Shen CH; Chang CB; Hsieh HY; Wu JD; Tseng LH; Hwang DW; Chen SY; Wu SF; Chan MWY; Hsu CD
    Mol Med; 2016 Sep; 22():64-73. PubMed ID: 26837068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model.
    de Queiroz NMGP; Marinho FV; de Araujo ACVSC; Fahel JS; Oliveira SC
    Sci Rep; 2021 Aug; 11(1):15648. PubMed ID: 34341449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
    Wu Q; Mahendran R; Esuvaranathan K
    Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
    O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
    J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF.
    Hu Z; Tan W; Zhang L; Liang Z; Xu C; Su H; Lu J; Gao J
    J Cell Mol Med; 2010 Jun; 14(6B):1836-44. PubMed ID: 19627402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation.
    Ren L; Yang X; Zhao L; Zhang H; Wang J
    Integr Cancer Ther; 2016 Mar; 15(1):80-6. PubMed ID: 26315609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
    Takeuchi A; Eto M; Tatsugami K; Shiota M; Yamada H; Kamiryo Y; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Takahashi R; Yokomizo A; Ohara N; Yoshikai Y
    Int Immunopharmacol; 2016 Jun; 35():327-331. PubMed ID: 27093372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model.
    Furuya H; Chan OTM; Pagano I; Zhu C; Kim N; Peres R; Hokutan K; Alter S; Rhode P; Rosser CJ
    J Transl Med; 2019 Jan; 17(1):29. PubMed ID: 30654801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
    Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
    Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.